Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-035821
Filing Date
2025-03-07
Accepted
2025-03-07 19:50:13
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 27635
  Complete submission text file 0000950170-25-035821.txt   29389
Mailing Address 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET SUITE 500 SAN FRANCISCO CA 94158 4158652050
COLUMN GROUP III, LP (Filed by) CIK: 0001668159 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Subject) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92757 | Film No.: 25721792
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)